{"disease":{"id":"squamous-cell-carcinoma-head-and-neck-cancer-hnscc","name":"squamous cell carcinoma head and neck cancer hnscc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06606028","title":"Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06366945","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT02383927","title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Kura Oncology, Inc.","has_results":true},{"nct_id":"NCT05980000","title":"Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT07149207","title":"Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Medical University of South Carolina","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}